Activation of the STAT3 signaling pathway is associated with poor survival in diffuse large B-cell lymphoma treated with R-CHOP

Journal of Clinical Oncology

Volumn 31, Issue 36, 2013, Pages 4520-4528

  Huang, Xin ^a,c   Meng, Bin ^a,c   Iqbal, Javeed ^c   Ding, B Belinda ^d   Perry, Anamarija M ^c   Cao, Wenfeng ^a,c   Smith, Lynette M ^c   Bi, Chengfeng ^b,c   Jiang, Chunsun ^c   Greiner, Timothy C ^c   Weisenburger, Dennis D ^c   Rimsza, Lisa ^e   Rosenwald, Andreas ^f   Ott, German ^g   Delabie, Jan ^g   Campo, Elias ^h   Braziel, Rita M ⁱ   Gascoyne, Randy D ^j   Cook, James R ^k   Tubbs, Raymond R ^k   Jaffe, Elaine S ^l   Armitage, James O ^c   Vose, Julie M ^c   Staudt, Louis M ^l   McKeithan, Timothy W ^c   Chan, Wing C ^c   Ye, B Hilda ^d   Fu, Kai ^a,c   more..

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF ARIZONA   (United States)

^f UNIVERSITY OF WÜRZBURG   (Germany)

^g UNIVERSITY OF OSLO   (Norway)

^h HOSPITAL CLÍNIC   (Spain)

ⁱ OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^j BRITISH COLUMBIA CANCER AGENCY   (Canada)

^k LERNER RESEARCH INSTITUTE   (United States)

^l NATIONAL CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; PROTEIN BCL 2; RITUXIMAB; STAT3 PROTEIN; VINCRISTINE; ANTINEOPLASTIC AGENT; CD20 ANTIGEN; MESSENGER RNA; MONOCLONAL ANTIBODY; STAT3 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CLINICAL FEATURE; DISEASES; EVENT FREE SURVIVAL; FEMALE; GENE EXPRESSION; HUMAN; INTERNATIONAL PROGNOSTIC INDEX; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SIGNAL TRANSDUCTION; ANALYSIS OF VARIANCE; DISEASE FREE SURVIVAL; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; LYMPHOMA, LARGE B-CELL, DIFFUSE; METABOLISM; MIDDLE AGED; MORTALITY; PREDICTIVE VALUE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; TISSUE MICROARRAY; TREATMENT OUTCOME; DRUG EFFECT;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PREDNISONE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RNA, MESSENGER; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME; VINCRISTINE;

EID: 84894580544     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.45.6004     Document Type: Article

References (45)

1. Anderson JR, Armitage JO, Weisenburger DD: Epidemiology of the non-Hodgkin's lymphomas: Distributions of the major subtypes differ by geographic locations - Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 9:717-720, 1998 (Pubitemid 28394156)
2. Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242, 2002 (Pubitemid 34438862)
3. Lenz G, Staudt LM: Aggressive lymphomas. N Engl J Med 362:1417-1429, 2010
4. Rosenwald A, Wright G, Chan WC, et al: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937-1947, 2002 (Pubitemid 34651353)
5. Alizadeh AA, Eisen MB, Davis RE, et al: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403: 503-511, 2000 (Pubitemid 30082188)
6. Davis RE, Brown KD, Siebenlist U, et al: Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 194:1861-1874, 2001 (Pubitemid 34028664)
7. Ding BB, Yu JJ, Yu RY, et al: Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood 111:1515-1523, 2008 (Pubitemid 351213441)
8. Lam LT, Wright G, Davis RE, et al: Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor- {kappa}B pathways in subtypes of diffuse large B-cell lymphoma. Blood 111:3701-3713, 2008
9. Wright G, Tan B, Rosenwald A, et al: A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A 100:9991-9996, 2003 (Pubitemid 37087056)
10. Pfreundschuh M, Ho AD, Cavallin-Stahl E, et al: Prognostic significance of maximum tumour (bulk) diameter in young patients with goodprognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: An exploratory analysis of the MabThera International Trial Group (MInT) study. Lancet Oncol 9:435-444, 2008
11. Sehn LH, Donaldson J, Chhanabhai M, et al: Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 23:5027-5033, 2005 (Pubitemid 46224009)
12. Fu K, Weisenburger DD, Choi WW, et al: Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol 26:4587-4594, 2008
13. Lenz G, Wright G, Dave SS, et al: Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 359:2313-2323, 2008
14. Darnell JE: Validating Stat3 in cancer therapy. Nat Med 11:595-596, 2005
15. Yu H, Pardoll D, Jove R: STATs in cancer inflammation and immunity: A leading role for STAT3. Nat Rev Cancer 9:798-809, 2009
16. Nelson EA, Walker SR, Kepich A, et al: Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3. Blood 112:5095-5102, 2008
17. Bailey TL, Boden M, Buske FA, et al: MEME SUITE: Tools for motif discovery and searching. Nucleic Acids Res 37:W202-W208, 2009
18. Kube D, Holtick U, Vockerodt M, et al: STAT3 is constitutively activated in Hodgkin cell lines. Blood 98:762-770, 2001
19. Chiarle R, Simmons WJ, Cai H, et al: Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med 11:623-629, 2005 (Pubitemid 40868302)
20. Ngo VN, Young RM, Schmitz R, et al: Oncogenically active MYD88 mutations in human lymphoma. Nature 470:115-119, 2011
21. Gupta M, Han JJ, Stenson M, et al: Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: Implications for therapy. Leukemia 26:1356-1364, 2012
22. Scuto A, Kujawski M, Kowolik C, et al: STAT3 inhibition is a therapeutic strategy for ABC-like diffuse large B-cell lymphoma. Cancer Res 71:3182-3188, 2011
23. Wu ZL, Song YQ, Shi YF, et al: High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma. J Hematol Oncol 4:31, 2011
24. Shaknovich R, Geng H, Johnson NA, et al: DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma. Blood 116: e81-e89, 2010
25. Choi WW, Weisenburger DD, Greiner TC, et al: A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 15:5494-5502, 2009
26. Iqbal J, Meyer PN, Smith LM, et al: BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab. Clin Cancer Res 17:7785-7795, 2011
27. Narimatsu M, Maeda H, Itoh S, et al: Tissuespecific autoregulation of the stat3 gene and its role in interleukin-6-induced survival signals in T cells. Mol Cell Biol 21:6615-6625, 2001 (Pubitemid 32927428)
28. Lam LT, Davis RE, Ngo VN, et al: Compensatory IKKalpha activation of classical NF-kappaB signaling during IKKbeta inhibition identified by an RNA interference sensitization screen. Proc Natl Acad Sci U S A 105:20798-20803, 2008
29. Brocke-Heidrich K, Ge B, Cvijic H, et al: BCL3 is induced by IL-6 via Stat3 binding to intronic enhancer HS4 and represses its own transcription. Oncogene 25:7297-7304, 2006 (Pubitemid 44809095)
30. Takeda T, Kurachi H, Yamamoto T, et al: Crosstalk between the interleukin-6 (IL-6)-JAK-STAT and the glucocorticoid-nuclear receptor pathway: Synergistic activation of IL-6 response element by IL-6 and glucocorticoid. J Endocrinol 159:323-330, 1998 (Pubitemid 28520186)
31. Bair E, Tibshirani R: Semi-supervised methods to predict patient survival from gene expression data. PLoS Biol 2:E108, 2004
32. Simon R, Peng A: BRB-ArrayTools User Guide, version 4.2.0-Beta 1. Bethesda, MD, Biometric Research Branch, National Cancer Institute, 2011
33. Altman DG, Vergouwe Y, Royston P, et al: Prognosis and prognostic research: Validating a prognostic model. BMJ 338:b605, 2009
34. Rosen DG, Mercado-Uribe I, Yang G, et al: The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis. Cancer 107:2730-2740, 2006 (Pubitemid 44845630)
35. Birner P, Toumangelova-Uzeir K, Natchev S, et al: STAT3 tyrosine phosphorylation influences survival in glioblastoma. J Neurooncol 100:339-343, 2010
36. Kim DY, Cha ST, Ahn DH, et al: STAT3 expression in gastric cancer indicates a poor prognosis. J Gastroenterol Hepatol 24:646-651, 2009
37. Gupta M, Maurer MJ, Wellik LE, et al: Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP. Blood 120: 4400-4406, 2012
38. Rasiah KK, Gardiner-Garden M, Padilla EJ, et al: HSD17B4 overexpression, an independent biomarker of poor patient outcome in prostate cancer. Mol Cell Endocrinol 301:89-96, 2009
39. Lee DG, Lee JH, Choi BK, et al: H(-)-myoinositol transporter SLC2A13 as a potential marker for cancer stem cells in an oral squamous cell carcinoma. Curr Cancer Drug Targets 11:966-975, 2011
40. Arriaga JM, Levy EM, Bravo AI, et al: Metallothionein expression in colorectal cancer: Relevance of different isoforms for tumor progression and patient survival. Hum Pathol 43:197-208, 2012
41. Chun JH, Kim HK, Kim E, et al: Increased expression of metallothionein is associated with irinotecan resistance in gastric cancer. Cancer Res 64:4703-4706, 2004 (Pubitemid 38924509)
42. Janakiram M, Thirukonda VK, Sullivan M, et al: Emerging therapeutic targets in diffuse large B-cell lymphoma. Curr Treat Options Oncol [epub ahead of print on February 2, 2012]
43. Nardella C, Chen Z, Salmena L, et al: Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events. Genes Dev 22:2172-2177, 2008
44. Lenz G, Wright GW, Emre NC, et al: Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A 105:13520-13525, 2008
45. Wang S, Tian C, Xing G, et al: ARF-dependent regulation of ATM and p53 associated KZNF (Apak) protein activity in response to oncogenic stress. FEBS Lett 584:3909-3915, 2010